Diabetes Technology Across the Lifespan of People With Diabetes (Ages 2-88 Years): Insights From the dt-Report on Usage Trends Across all Age Groups
Authors' conclusion
Diabetes technologies are widely used and well tolerated across age groups. Older adults benefit comparably, but barriers to AID use remain.
Study context
- Population
- People with T1D or T2D in Germany, Austria and Switzerland who completed the diabetes technology report 2024/2025 survey (self-reported data)
- Participants
- 2,056 people
- Outcome
- Age-related trends in diabetes technology use
Methodological detailsself-reported survey, multinational
- Self-reported survey
- Multinational
Main finding
As reported in the abstract
- T1D: Continuous glucose monitoring (CGM) use, 20-29 years
- 94%
- T1D: CGM use, ≥70 years
- 92%
- T1D: Automated insulin delivery (AID) use, 10-19 years (peak)
- 81%
- T1D: AID use, adults ≥70 years
- 36%
- T2D: CGM use, 35-44 years
- 48%
- T2D: CGM use, ≥70 years
- 72%
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Diabetes distress (PAID-5) | <30 years 7.8 · ≥70 years 4.2 |
| AID satisfaction (AID users) | 60 to 69 years 88.7 /100 · Adolescents 79.1 /100 |
HbA1c over the age span
- HbA1c remained stable over the age span
- ±0.25%
Diabetes distress (PAID-5)
- Diabetes distress declined with age
AID satisfaction (AID users)
- Highest in adults aged 60 to 69 years, lowest in adolescents
Safety
| Outcome | OR | P value |
|---|---|---|
| Severe hypoglycaemiaOlder CSII users vs Younger CSII users | 0.03 | P = 0.001 |
Severe hypoglycaemia
- Risk of severe hypoglycemia (SH) did not increase with age
Original publication
Diabetes Technology Across the Lifespan of People With Diabetes (Ages 2-88 Years): Insights From the dt-Report on Usage Trends Across all Age Groups. J Diabetes Sci Technol. Published 8 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →